Details

Autor(en) / Beteiligte

• Vermi, William
• Soncini, Matias
• Melocchi, Laura
• Sozzani, Silvano
• Facchetti, Fabio

Titel

Plasmacytoid dendritic cells and cancer

Ist Teil von

• Journal of leukocyte biology, 2011-10, Vol.90 (4), p.681-690

Ort / Verlag

United States: Society for Leukocyte Biology

Erscheinungsjahr

2011

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Review on plasmacytoid dendritic cells biology with emphasis on their role in cancer immunity. Cancer develops in a complex microenvironment comprising cancer cells, stromal cells, and host immune cells with their soluble products. The counteracting host‐protective and tumor‐promoting roles of different immune cell populations have been elegantly clarified in the last decade by pertinent genetically modified mouse models. Among cells with a potential role in cancer immunity, PDCs might represent important players as a result of their capacity to bring together innate and adaptive immunity. This review summarizes current knowledge about the role of PDCs in cancer immunity. PDCs have been documented in primary and metastatic human neoplasms; however, the clinical significance of this finding is still unknown. Once into the tumor bed, PDCs can be hijacked by the tumor microenvironment and lose their propensity to produce the required amount of endogenous I‐IFN. However, when properly reprogrammed (i.e., by TLR agonists), PDCs might mediate tumor rejection in a clinical setting. Tumor rejection, at least partially, is driven by I‐IFN and seems to require a cross‐talk with other innate immune cells, including IFN DCs. The latter evidence, although still limited to skin cancers, can provide a leading model for developing adjuvant immune therapy for other neoplasms. To this end, the generation of appropriate mouse models to modulate the frequency and activation state of murine PDCs will also be of remarkable importance.